So the information ends up being post-hoc analysis for patients with T2D, CKD with <60 eGFR levels, receiving top standard of care with apabetalone vs top standard of care receiving a placebo. This hopefully will show an increase in the eGFR levels in the Apabetalone group compared with the placebo group.

Koo